As interest in therapeutic TIDES grows, regulatory agencies are increasingly requiring more rigorous characterization to ensure patient safety, drug efficacy, and quality. To meet these demands, high-resolution analytical techniques are essential for structural characterization, helping to accelerate time to market and support Quality by Design (QbD) approaches.
Nuclear Magnetic Resonance (NMR) spectroscopy plays a key role in this process, offering deep structural insights through multi-nuclei perspectives in both 1D and 2D experiments.
Recent advancements in probe technology and ultra-high field innovations further enhance NMR’s capabilities, allowing scientists to expedite structural characterization for drug discovery and quality control.
What to expect
In this webinar, you will learn how to use the latest NMR probe and high magnetic field equipment advancements to accomplish enhanced structure characterization of TIDES which is relevant to current analytical challenges and regulatory requirements.
Key learning points
- Peptides and oligonucleotides (TIDES) are gaining popularity due to their demonstrated efficacy, which regulatory agencies are closely monitoring.
- High-resolution structure characterization requires cutting-edge techniques like NMR spectroscopy.
- New probe and equipment technologies improve NMR sensitivity and resolution for TIDES, leading to faster and more accurate analysis.
Who should attend?
This webinar is ideal for analytical or research scientists interested in enhancing the structural characterization of therapeutic TIDES. Additionally, any NMR spectroscopists working on drug projects should attend to stay up to date with the most recent NMR technologies available.
About the Speaker
Dr. Victor Beaumont researched and implemented NMR techniques throughout his undergraduate studies at the University of Buffalo (Dr. Thomas Szyperski) and doctoral studies at Yale University (Dr. Patrick Loria).
He eventually joined Pfizer as an NMR specialist for biotherapeutic structure characterization, progressing to project management for analytical laboratory automation.
His aim is to improve society's quality of life and working efficiencies by supporting and contributing high-quality scientific innovation, with an emphasis on cutting-edge NMR characterization of novel therapeutic modalities.
At Bruker, he collaborates with scientists to understand industry difficulties and demands to advance NMR applications and technology.